{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:58Z","timestamp":1790796238788,"version":"4.1.0"},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.2169\/internalmedicine.7115-21","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T22:09:06Z","timestamp":1637964546000},"page":"2013-2017","source":"Crossref","is-referenced-by-count":6,"title":["IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis"],"prefix":"10.2169","volume":"61","author":[{"given":"Yuki","family":"Mitarai","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Hamada Medical Center, Japan"},{"name":"Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shonan Fujisawa Tokushukai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45: 160-169, 2017.","DOI":"10.1159\/000455014"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104: 73-81, 1999.","DOI":"10.1172\/JCI5535"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kawamura T, Joh K, Okonogi H, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol 26: 350-357, 2013.","DOI":"10.5301\/jn.5000151"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Oki R, Hirakawa Y, Kimura H, et al. Renal effects after pembrolizumab treatment for non-small cell lung carcinoma: a case report. Intern Med 59: 977-981, 2020.","DOI":"10.2169\/internalmedicine.3928-19"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kishi S, Minato M, Saijo A, et al. IgA Nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med 57: 1259-1263, 2018.","DOI":"10.2169\/internalmedicine.9814-17"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Murakami N, Motwani S, Riella VL. Renal complications of immune checkpoint blockade. Curr Probl Cancer 41: 100-110, 2017.","DOI":"10.1016\/j.currproblcancer.2016.12.004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Katafuchi R, Nagae H, Masutani K, et al. Comprehensive evaluation of the significance of immunofluorescent findings on clinicopathological features in IgA nephropathy. Clin Exp Nephrol 23: 169-181, 2019.","DOI":"10.1007\/s10157-018-1619-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lee H-J, Choi SY, Jeong KW, et al. Association of C1q deposition with renal outcomes in IgA nephropathy. Clin Nephrol 80: 98-104, 2013.","DOI":"10.5414\/CN107854"},{"key":"10","unstructured":"10. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36: 1714-1768, 2018."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/13\/61_7115-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:15:01Z","timestamp":1715231701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/13\/61_7115-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":10,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7115-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"7115-21"}}